Rather than targeting fibronectin directly, a recent adaptation of the approach by Shi et al. delivered TF to microthrombus-associated fibrin-fibronectin complexes overexpressed on tumor vessel endothelium and tumor matrix [91]. The gene discussed is FN1; the disease is neoplasm.